In last trading session, Prime Medicine Inc (NASDAQ:PRME) saw 0.59 million shares changing hands with its beta currently measuring 2.19. Company’s recent per share price level of $3.46 trading at -$0.1 or -2.81% at ring of the bell on the day assigns it a market valuation of $415.30M. That closing price of PRME’s stock is at a discount of -201.16% from its 52-week high price of $10.42 and is indicating a premium of 2.02% from its 52-week low price of $3.39. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.76 million shares which gives us an average trading volume of 706.63K if we extend that period to 3-months.
For Prime Medicine Inc (PRME), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.45 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Prime Medicine Inc (NASDAQ:PRME) trade information
Upright in the red during last session for losing -2.81%, in the last five days PRME remained trading in the red while hitting it’s week-highest on Monday, 09/23/24 when the stock touched $3.46 price level, adding 9.9% to its value on the day. Prime Medicine Inc’s shares saw a change of -60.95% in year-to-date performance and have moved -9.66% in past 5-day. Prime Medicine Inc (NASDAQ:PRME) showed a performance of -18.01% in past 30-days. Number of shares sold short was 16.57 million shares which calculate 31.16 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 17 to the stock, which implies a rise of 79.65% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 23. It follows that stock’s current price would drop -246.82% in reaching the projected high whereas dropping to the targeted low would mean a loss of -246.82% for stock’s current value.
Prime Medicine Inc (PRME) estimates and forecasts
Statistics highlight that Prime Medicine Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -50.57% of value to its shares in past 6 months, showing an annual growth rate of 13.30% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.33M for the same. And 9 analysts are in estimates of company making revenue of 620k in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -193.88% during past 5 years.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Insiders are in possession of 26.27% of company’s total shares while institution are holding 68.08 percent of that, with stock having share float percentage of 92.33%. Investors also watch the number of corporate investors in a company very closely, which is 68.08% institutions for Prime Medicine Inc that are currently holding shares of the company.
